Erdafitinib or Chemotherapy in Advanced Pre-Treated Urothelial Carcinoma
Physician's Weekly,
1. The median overall survival was 12.1 months in the erdafitinib group and 7.8 months in the chemotherapy group, with an HR of…
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study
Overview of attention for article published in Lancet Oncology, January 2022
Altmetric Badge
About this Attention Score
-
In the top 5% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (97th percentile)
-
High Attention Score compared to outputs of the same age and source (82nd percentile)
Mentioned by
- news
- 7 news outlets
- blogs
- 1 blog
- 27 X users
- patent
- 2 patents
- guideline
- 3 clinical guideline sources
- podcasts
- 1 podcast
Readers on
- mendeley
- 109 Mendeley